Forsinkede kurser. Sist oppdatert: tirsdag 20. november  

07/06-2017 18:01:11: (NANO) Accepted abstract by ICML with updated results from Phase 1/2 trial of Betalutin® in NHL is now available on-line

Oslo, Norway, 7 June 2017

Nordic Nanovector ASA (OSE: NANO) announces that an abstract reporting updated
results from the ongoing LYMRIT 37-01 Phase 1/2 clinical study of Betalutin®
(177Lu-satetraxetan-lilotomab) in patients with relapsed/refractory non
-Hodgkin's lymphoma (NHL) accepted for a presentation at the International
Conference on Malignant Lymphoma (ICML; 14-17 June; Lugano, Switzerland), is now
available on-line -

An updated dataset on 59 patients (safety) and 47 patients (efficacy) will be
presented in a poster at the meeting on 15 June by Dr. Arne Kolstad, Senior
Consultant in Medical Oncology and Radiation Therapy at the Oslo University
Hospital, Norwegian Radium Hospital, and the study's Principal Investigator. The
poster will be available from 12:00pm CET on 14 June at
in the section: Product Info/Scientific Posters.

For further information, please contact:

IR enquiries:

Tone Kvåle, Chief Financial Officer

Cell: +47 91 51 95 76


Media enquiries:

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 282 2948/+44 207 282 2949


About Nordic Nanovector:

Nordic Nanovector is committed to develop and deliver innovative therapies to
patients to address major unmet medical needs and advance cancer care. The
company aspires to become a leader in the development of targeted therapies for
haematological cancers.

Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37
-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the
treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial
unmet medical need, representing a growing market forecast to be worth nearly
USD 20 billion by 2024.

The Company aims to rapidly develop Betalutin®, alone and in combination with
other therapies, for the treatment of major types of NHL, targeting first
regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019.
Nordic Nanovector intends to retain marketing rights and to actively participate
in the commercialisation of Betalutin® in core markets.

The Company is also advancing a pipeline of ARCs and other immunotherapies for
multiple cancer indications.

Further information about the Company can be found at

Forward-looking statements

This announcement may contain certain forward-looking statements and forecasts
based on uncertainty, since they relate to events and depend on circumstances
that will occur in the future and which, by their nature, will have an impact on
Nordic Nanovector's business, financial condition and results of operations. The
terms "anticipates", "assumes", "believes", "can", "could", "estimates",
"expects", "forecasts", "intends", "may", "might", "plans", "should",
"projects", "will", "would" or, in each case, their negative, or other
variations or comparable terminology are used to identify forward-looking
statement. There are a number of factors that could cause actual results and
developments to differ materially from those expressed or implied in a forward
-looking statement or affect the extent to which a particular projection is
realised. Factors that could cause these differences include, but are not
limited to, implementation of Nordic Nanovector's strategy and its ability to
further grow, risks associated with the development and/or approval of Nordic
Nanovector's products candidates, ongoing clinical trials and expected trial
results, the ability to commercialise Betalutin®, technology changes and new
products in Nordic Nanovector's potential market and industry, the ability to
develop new products and enhance existing products, the impact of competition,
changes in general economy and industry conditions and legislative, regulatory
and political factors. No assurance can be given that such expectations will
prove to have been correct. Nordic Nanovector disclaims any obligation to update
or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

This information is subject to a duty of disclosure pursuant to Section 5-12 of
the Securities Trading Act.

Ekstern link:

Nyheten er levert av OBI.